Causaly vs CoCounsel (2026)

Causaly

by Causaly

CoCounsel

by Thomson Reuters

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases including target identification, drug repositioning, mechanism of action investigation, and safety assessment produce outputs with traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• ⚠Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• ⚠Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• ⚠Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/month) or ChatGPT Deep Research ($20/month) substantially more cost-effective outside pharma R&D workflows.

Pros

• ✓Grounded in Westlaw proprietary content: research outputs cite authoritative primary sources with editorial enhancements rather than open-web content, providing the citation reliability that legal work demands and that no competitor without proprietary legal databases can match.
• ✓Deep Research agentic capability creates research plans, executes queries iteratively across Westlaw, and delivers comprehensive reports with transparent reasoning chains, handling multi-step legal research workflows that previously required hours of attorney time.
• ✓Institutional adoption at a scale no legal AI competitor approaches: majority of Am Law 100, 100% of Fortune 100, 97% of Fortune 1000, all US federal courts, and 1M+ total users across legal, tax, audit, and accounting professions.

Limitations

• ⚠Westlaw bundling means some buyers pay for legal research infrastructure they may not need: firms already committed to Lexis+ or vLex face switching costs, and the subscription commitment with Westlaw Precision represents significant annual spend for smaller practices.
• ⚠Pricing requires sales engagement: the $428/month MSBA reference is one data point, but actual rates vary by jurisdiction, headcount, modules, and contract length, making cost comparison against alternatives difficult without a Thomson Reuters conversation.
• ⚠Pre-built workflow library is the primary capability: custom workflows are rolling out incrementally, meaning firms with highly specialized or non-standard legal processes may find the current workflow options do not cover their specific needs.